Across TCGA pan-cancer cohorts, ABHD17AP1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ABHD17AP1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ABHD17AP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ABHD17AP1 is over-expressed in tumor.

KIRC, COAD, and LIHC are the cancer types where ABHD17AP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD17AP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.216	<.001	9	view →
COAD	All	II,III,IV	+0.232	.007	5	view →
LIHC	Female	All	+0.210	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ABHD17AP1 RNA expression & survival · all ABHD17AP1 data types